Omaha, Neb., October 24, 2018 — Meridian Clinical Research will attend the 19th World Vaccine Congress (WVC) in Lisbon, Portugal from October 29 to 31. As a leading investigative site network for vaccines and infectious diseases, Meridian will have several representatives at the conference.
At the event, Brandon Essink, MD, medical director and principal investigator at Meridian, will lead an interactive roundtable session, “Eyes wide open: What your sites want to tell you!” The back-to-back roundtables will begin at 11:40 a.m. on October 29.
Earlier this year, Dr. Essink co-authored an article published in Vaccine as part of a successful clinical trial for a meningococcal disease (meningitis) vaccine. He is frequently chosen to lead pioneering vaccine research studies because of his extensive vaccine experience and the high performance of sites under his guidance. In these roundtables, Dr. Essink will share his perspective with representatives from pharmaceutical companies and contract research organizations.
“We’re happy to have Dr. Essink join us in Lisbon,” said Wes Bonner, vice president of business development at Meridian. “He’s an authority in running vaccine studies, and many of our clients ask for his input when developing vaccine-related protocols.”
Meridian will also attend the Central Nervous System (CNS) Summit from November 1-4 in Boca Raton, Fla. The company conducts clinical trials at numerous neurological centers nationwide. These neurology centers are highly-regarded in their communities, and frequently conduct studies for Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and migraines. Additionally, results from clinical trials performed at Meridian were recently published in the Journal of Psychiatric Research.
If you’d like to learn more about Meridian at WVC Europe or the CNS Summit, request a meeting by visiting mcrmed.com.
About Meridian Clinical Research
Meridian Clinical Research partners with pharmaceutical and biotechnology companies to research new pharmaceutical drugs, medical devices, and diagnostics that could improve human health and wellbeing. Founded in 1999, Meridian is headquartered at a dedicated research center in Omaha, NE, and conducts Phase I-IV studies at 18 investigative sites across North America. Meridian supports research across numerous therapeutic areas and specializes in high-volume vaccine trials. For more information, visit www.mcrmed.com.